support from the National Natural Science Foundation of China(Nos.22277110 and 82003585)and Tianjian Laboratory of Advanced Biomedical Sciences.
Lenacapavir,also known as GS-6207,under the brand name Sunlenca,was developed by Gilead Sciences Inc.It has been approved in the EU,Canada,and US for use alongside other antiretrovirals in adults with multidrug-resist...
The authors declare that in the correspondence“Preexisting low-frequency resistance mutations increase the risk of antiretroviral treatment failure in HIV-1 naïve patients”[1]which was published in vol.136,issue 22,...
Context and objective: Around 8% of incident cases of tuberculosis (TB) were reported among people living with HIV worldwide in 2022. Tuberculosis is the leading cause of death among people living with HIV. Africa acc...
supported by the 2020 Annual Medical Research Project of Jiangsu Commission of Health(No.ZDA 2020014);the Key Project supported by Medical Science and Technology Development Foundation,Nanjing Department of Health(Nos.ZKX 22040 and ZKX 19048)
To the Editor:High-frequency resistance(typically≥15-25%viral quasispecies)detected by conventional resistance assays has long been associated with failure of antiretroviral therapy(ART)to suppress viral replication,...
Background:Effective two-drug regimens could decrease long-term drug exposure and toxicity with HIV-1 antiretroviral therapy(ART).We therefore aimed to evaluate the efficacy and safety of a two-drug regimen compared w...
Background:HIV-1 Vpu acts by counteracting the tethering function of tetherin and resulting in the release of HIV-1 virion.Disrupting Vpu-tetherin interactions may provide a promising new target for antiretroviral the...
Summary What is already known on this topic?Men who have sex with men(MSM)in China have a high rate of human immunodeficiency virus(HIV)infection.Pre-exposure prophylaxis(PrEP)and postexposure prophylaxis(PEP)have bee...
This paper mainly targets to deduce an optimal treatment strategy for combined antiretroviral drugs,which can maximize healthy CD4^(+)T cells level with minimum side effects and cost.For this purpose,we consider a wit...
supported by the Major National Science and Technology Projects during the 13th 5-year plan period(2017ZX10202101-003,2017ZX10202102-003-004);the Guangzhou Science and Technology Innovation Committee project(new strategy for functional cure of AIDS–clinical and basic research,201803040002);Guangzhou basic research program on people’s Livelihood Science and technology(No.202002020005).
Background:With the high prevalence of pre-treatment drug resistance(PDR)and the potential impact to the virological inhibition,the detection of PDR was particularly necessary.This study aimed to determine the prevale...
Guangzhou Basic Research Program on People’s Livelihood Science and Technology(No. 202002020005);National Natural Science Foundation of China(No. 82072265);Chinese 13th Five-Year National Science and Technology Major Project(No. 2017ZX10202101-003-001)。
Background: Chronic liver disease has emerged as a leading cause of non-acquired immune deficiency syndrome (AIDS)-related mortality in hepatitis C virus (HCV)/human immunodeficiency virus (HIV)-coinfected patients. T...